olaratumab + ifosfamide

Olaratumab + ifosfamide is a combination regimen investigated for the treatment of soft tissue sarcoma. **Olaratumab** is a monoclonal antibody targeting **platelet-derived growth factor receptor alpha (PDGFRα)**, blocking its activation and downstream signaling involved in tumor growth. **Ifosfamide** is an alkylating agent that crosslinks DNA, causing cell death. The combination aims to enhance antitumor effects, particularly in soft tissue sarcomas, where PDGFRα signaling may promote proliferation and resistance. Preliminary studies indicate this combination, sometimes with doxorubicin, is active and its safety is generally comparable to established regimens[1][2][4].